Cardiothoracic & vascular anesthesia
Amino Acid Infusion for Kidney Protection in Cardiac Surgery Patients with Chronic Kidney Disease: A Secondary Analysis of the PROTECTION Trial
Primary result · AKIResult — go to the resultRelative risk 0.86 95% CI 0.74–0.99Authors' conclusion
Amino acid infusion protected chronic kidney disease patients undergoing cardiopulmonary bypass from developing acute kidney injury, with an absolute risk reduction of 7% and a number needed to treat of 14 in a cohort with a greater than 45% rate of acute kidney injury. Moreover, it delivered a greater than 50% relative risk reduction in severe acute kidney injury.
Study context
- Population
- Cardiac surgery patients with CPB and CKD (eGFR <60 ml · min −1 · 1.73 m −2)
- Participants
- 812 CKD patients
- Comparison
- Amino acids vs Placebo
- Primary endpoint
- Occurrence of AKI
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
AKI
Relative risk
0.86
95% CI 0.74–0.99
P = 0.041
By group
Amino acids vs Placebo
RR 0.86 (95% CI 0.74–0.99); P = 0.041
As reported in the abstract
Secondary outcomes
| Outcome | Amino acids | Placebo | RR (95% CI) | P value | |
|---|---|---|---|---|---|
| Severe (stage 3) AKI | 2.7% | 5.6% | 0.48 (0.24–0.98) | P = 0.038 | |
| 0.20.5125Relative risk (log scale) |
Median
| Outcome | Amino acids | Placebo | P value |
|---|---|---|---|
| Median percentage increase in eGFR from baseline · postoperative day 3 | 12.7% | 6.5% | P = 0.002 |
AKI by eGFR-based CKD subgroup (30 to 39, 40 to 49, 50 to 59 ml · min −1 · 1.73 m −2) (subgroup)
- Amino acid effect similar across subgroups
- Interaction P = 0.50
Original publication
Amino Acid Infusion for Kidney Protection in Cardiac Surgery Patients with Chronic Kidney Disease: A Secondary Analysis of the PROTECTION Trial. Anesthesiology. Published 19 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →